CliffBio
small molecule

LAMICTAL XR

LAMOTRIGINE

Loss of exclusivityJanuary 2029latest FDA-listed patent expiry
CompanyGlaxoSmithKline →View the full company profile on CliffBio

Drug detail

Brand nameLAMICTAL XR
Active ingredientLAMOTRIGINE
Strength250MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2011
Marketing statusRX

Listed patents

PatentExpiresType
8637512January 2029product

More from GlaxoSmithKline

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LAMICTAL XR patent cliff — loss of exclusivity January 2029 | CliffBio